Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 227,337 shares at $18.38 ($4.2M) on 2026-04-28, disclosed to the SEC on 2026-04-30.
Scheduled sale ($4.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.38 | 119,115 | $2.2M | 52.4% |
| 2 | $18.38 | 1,170 | $22K | 0.5% |
| 3 | $18.38 | 47,082 | $865K | 20.7% |
| 4 | $18.38 | 59,870 | $1.1M | 26.3% |
| 5 | $19.00 | 1 | $19 | 0.0% |
| 6 | $19.00 | 21 |
| $399 |
| 0.0% |
| 7 | $19.00 | 26 | $494 | 0.0% |
| 8 | $19.00 | 52 | $988 | 0.0% |
| Total | $18.38 avg | 227,337 | $4.2M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |